Special Issue "Gene Therapy"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (20 September 2012)

Special Issue Editor

Guest Editor
Prof. Dr. Leonidas A. Phylactou
Acting Chief Executive Medical Director, Department of Molecular Genetics, Function & Therapy, The Cyprus Institute of Neurology & Genetics, PO Box 23462, 1683 Nicosia, Cyprus
Website: http://www.cing.ac.cy/mgft/
E-Mail: laphylac@cing.ac.cy
Interests: RNA biology; regulatory RNA molecules; muscle regeneration, identification of genetic defects in inherited diseases

Special Issue Information

Dear Colleagues,

Gene therapy is considered very promising for the therapy of several diseases, whether these are inherited or acquired during life. Although it is a field which has peaked relatively recently, the rationale behind all the gene therapy approaches are based on fundamental genetics and molecular biology, aiming at interfering at all stages of the flow of the genetic information. Currently, gene therapy protocols are developed for the delivery of genetic material with viral and non-viral methods, the down-regulation of gene expression at the DNA, RNA and protein levels (anti-gene, RNA interference, antisense, ribozymes, aptamers etc) and the expression of transgenes and genetic sequences. Gene therapy is now advanced against several common and rare diseases. For example, several approaches are being developed for the therapy of cancer, diabetes, cardiovascular diseases, infectious and inherited disorders. Some of these approaches are at the pre-clinical stage but some have progressed to clinical trials. Gene therapy is the way to treat several diseases in the future and research progress in this field has shown that this is achievable.

Dr. Leonidas A. Phylactou
Guest Editor

Keywords

  • gene therapy
  • viral vectors
  • non-viral vectors
  • antisense
  • RNA interference
  • ribozymes
  • aptamers
  • inducible expression
  • tissue-specific expression
  • genome modification

Published Papers (6 papers)

by  and
Pharmaceuticals 2013, 6(7), 813-836; doi:10.3390/ph6070813
Received: 13 May 2013; in revised form: 14 June 2013 / Accepted: 14 June 2013 / Published: 27 June 2013
Show/Hide Abstract | PDF Full-text (682 KB) | HTML Full-text | XML Full-text

by , ,  and
Pharmaceuticals 2012, 5(12), 1372-1392; doi:10.3390/ph5121372
Received: 16 November 2012; in revised form: 5 December 2012 / Accepted: 6 December 2012 / Published: 10 December 2012
Show/Hide Abstract | PDF Full-text (419 KB) | HTML Full-text | XML Full-text

by , Júnior, , , ,  and
Pharmaceuticals 2012, 5(6), 643-654; doi:10.3390/ph5060643
Received: 17 May 2012; in revised form: 9 June 2012 / Accepted: 13 June 2012 / Published: 18 June 2012
Show/Hide Abstract | Cited by 1 | PDF Full-text (442 KB) | HTML Full-text | XML Full-text

by ,  and
Pharmaceuticals 2012, 5(6), 553-590; doi:10.3390/ph5060553
Received: 17 April 2012; in revised form: 18 May 2012 / Accepted: 23 May 2012 / Published: 4 June 2012
Show/Hide Abstract | PDF Full-text (442 KB) | HTML Full-text | XML Full-text
abstract graphic

by , , ,  and
Pharmaceuticals 2012, 5(5), 447-459; doi:10.3390/ph5050447
Received: 20 February 2012; in revised form: 3 April 2012 / Accepted: 19 April 2012 / Published: 2 May 2012
Show/Hide Abstract | PDF Full-text (572 KB) | HTML Full-text | XML Full-text

by , , , , ,  and
Pharmaceuticals 2011, 4(10), 1381-1399; doi:10.3390/ph4101381
Received: 1 August 2011; in revised form: 3 October 2011 / Accepted: 11 October 2011 / Published: 24 October 2011
Show/Hide Abstract | Cited by 3 | PDF Full-text (518 KB) | HTML Full-text | XML Full-text
abstract graphic

Last update: 4 March 2014

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert